Punjab will have a dry run for vaccination drive before Covid-19 vaccination process, all arrangements will be tested
Before the introduction of the Covid-19 vaccine, the Central Government has expedited the preparation of the trial of the vaccination drive. The central government has chosen the cities of Punjab for the dry run. There will be a trial of vaccination drive on December 28 and 29 at five places in Ludhiana and Shaheed Bhagat Singh Nagar in Punjab. The purpose of this trial is to investigate the discussed methods for starting Covid-19 vaccination.
State Health Minister Balbir Singh Sidhu said, ‘Ludhiana and Shaheed Bhagat Singh Nagar districts have been selected for vaccination trials. The purpose of this trial is to test the procedure prescribed for vaccination in the health system. This will explain the flaws that can be removed before starting the Covid-19 vaccination. The trial will be done under the leadership of the District Magistrate in one or two districts. The trial is proposed in four states – Andhra Pradesh, Assam, Gujarat and Punjab.
A Co-Win mobile app has been developed to register for the Covid-19 vaccine. During the dry run, the status of this app will be examined. Through this app, information related to the vaccine and the necessary data will be updated online.
1,000 Volunteer Ready to Take the Second Dose of
The first dose of Corona Vaccine ‘Covaxin’ developed in the country was successful with 1,000 Volunteers at Prakhar Hospital as part of a Phase III trial. Dr JS Kushwaha, the principal investigator of Prakhar Hospital, said, “The second dose of Covaxin will also be given to these 1,000 volunteers from January 1. The first dose of this vaccine was given to volunteers from various communities.”
The first group of volunteers was vaccinated on 5 December and the campaign continued until 21 December. It took 17 days to deliver Covaxin to these 1,000 volunteers.
Bharat Biotech recruited 13,000 volunteers for the third trial of Covaxin
Bharat Biotech announced the successful recruitment of 13,000 volunteers on Tuesday and targeted 26,000 participants for the Phase III clinical trial of its CoronaVirus Vaccine ‘Covaxin’. The third phase of the Covaxin trial began in mid-November, with a target of 26,000 volunteers across India.
India’s indigenous Covid-19 vaccine Covaxin has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).